Chronic prostatitis is a common urological disease. The etiology of this disease and effective therapy for its treatment are yet to be elucidated. We investigated the functions of XLQ((R)) in chronic nonbacterial prostatitis using a complete Freund's adjuvant-induced rat model. Prostates and blood samples were collected for further evaluation after oral gavage with XLQ ((R)) or a vehicle for 4 weeks. The results showed that XLQ ((R)) significantly decreased the prostate index, ameliorated the histopathologic changes, and reduced CD3+ and CD45+ cell infiltration in the prostate stroma. Further study showed that XLQ ((R)) suppressed the expression of proinflammatory cytokines, such as interleukin (IL)-1 beta, IL-2, IL-6, IL-17A, monocyte chemoattractant protein-1, and tumor necrosis factor-alpha. XLQ ((R)) showed a strong antioxidant capacity by enhancing the activities of antioxidative enzymes (e.g., total superoxide dismutase, catalase, and glutathione peroxidase) and decreasing the level of lipid peroxidation products (malondialdehyde). Moreover, XLQ ((R)) can suppress the activation of nuclear factor-kappa B and P38-mitogen-activated protein kinase signaling pathways. In summary, XLQ ((R)) has affirmative effects on chronic prostatitis, which could be attributed to its anti-inflammatory and antioxidative capacities. On the basis of these results, XLQ ((R)) can be developed as an effective and safe therapy for chronic prostatitis.